Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

1.

Effect of caffeine on ceftriaxone disposition and plasma protein binding in the rat.

Kwon KI, Bourne DW.

J Pharmacokinet Biopharm. 1986 Aug;14(4):397-408. Erratum in: J Pharmacokinet Biopharm 1987 Jun;15(3):345.

PMID:
3689487
[PubMed - indexed for MEDLINE]
2.

Effect of caffeine on the plasma protein binding and the disposition of ceftriaxone.

Kwon KI, Bourne DW, Ho PC.

J Pharm Pharmacol. 1985 Nov;37(11):836-9.

PMID:
2867172
[PubMed - indexed for MEDLINE]
3.

Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.

Lopes de Menezes DE, Mayer LD.

Cancer Chemother Pharmacol. 2002 Jan;49(1):57-68.

PMID:
11855753
[PubMed - indexed for MEDLINE]
4.

Disposition kinetics and dosage regimen of ceftriaxone in crossbred calves (short communication).

Johal B, Srivastava AK.

Acta Vet Hung. 1999;47(2):243-8.

PMID:
10344084
[PubMed - indexed for MEDLINE]
5.

Plasma protein binding of ceftriaxone.

Popick AC, Crouthamel WG, Bekersky I.

Xenobiotica. 1987 Oct;17(10):1139-45.

PMID:
3424863
[PubMed - indexed for MEDLINE]
6.

Effect of probenecid on the elimination and protein binding of ceftriaxone.

Stoeckel K, Trueb V, Dubach UC, McNamara PJ.

Eur J Clin Pharmacol. 1988;34(2):151-6.

PMID:
3383987
[PubMed - indexed for MEDLINE]
7.

[Disposition of 3-(N-piperidinomethylarino)methyl-rifamycin SV (FCE 22250) in rats].

Liu L, Wang ZY, Li D, Sun SL.

Zhongguo Yao Li Xue Bao. 1991 Jan;12(1):58-62. Chinese.

PMID:
1950587
[PubMed - indexed for MEDLINE]
Free Article
8.

Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH.

Clin Pharmacol Ther. 1981 May;29(5):650-7.

PMID:
7053242
[PubMed - indexed for MEDLINE]
9.

Characterization of the relationship between serum and milk residue disposition of ceftriaxone in lactating ewes.

Goudah A, Shin HC, Shim JH, Abd El-Aty AM.

J Vet Pharmacol Ther. 2006 Aug;29(4):307-12.

PMID:
16846468
[PubMed - indexed for MEDLINE]
10.

Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.

Stecklair KP, Hamburger DR, Egorin MJ, Parise RA, Covey JM, Eiseman JL.

Cancer Chemother Pharmacol. 2001 Nov;48(5):375-82.

PMID:
11761455
[PubMed - indexed for MEDLINE]
11.

Disposition of ceftriaxone in rat: application of a pharmacokinetic-protein binding model and comparison with cefotaxime.

Hakim L, Bourne DW, Triggs EJ.

Xenobiotica. 1989 Aug;19(8):815-22.

PMID:
2815824
[PubMed - indexed for MEDLINE]
12.

Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat.

Bortolotti A, Jiritano L, Bonati M.

Drug Metab Dispos. 1985 Mar-Apr;13(2):227-31.

PMID:
2859173
[PubMed - indexed for MEDLINE]
13.

Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.

McNamara PJ, Gibaldi M, Stoeckel K.

Eur J Clin Pharmacol. 1983;25(3):407-12.

PMID:
6313380
[PubMed - indexed for MEDLINE]
14.

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.

Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, Eiseman JL.

Cancer Chemother Pharmacol. 2002 Jan;49(1):7-19.

PMID:
11855755
[PubMed - indexed for MEDLINE]
15.

Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats.

Tsuji A, Yoshikawa T, Nishide K, Minami H, Kimura M, Nakashima E, Terasaki T, Miyamoto E, Nightingale CH, Yamana T.

J Pharm Sci. 1983 Nov;72(11):1239-52.

PMID:
6644585
[PubMed - indexed for MEDLINE]
16.

Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis.

Kovar A, Dalla Costa T, Derendorf H.

J Pharm Sci. 1997 Jan;86(1):52-6.

PMID:
9002459
[PubMed - indexed for MEDLINE]
17.

Single-dose ceftriaxone kinetics in the newborn.

Schaad UB, Hayton WL, Stoeckel K.

Clin Pharmacol Ther. 1985 May;37(5):522-8.

PMID:
3987175
[PubMed - indexed for MEDLINE]
18.

Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Keller F, Maiga M, Neumayer HH, Lode H, Distler A.

Eur J Drug Metab Pharmacokinet. 1984 Jul-Sep;9(3):275-82.

PMID:
6519129
[PubMed - indexed for MEDLINE]
19.

Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.

Leung KH, Cohn DA, Miller RR, Doss GA, Stearns RA, Simpson RE, Feeney WP, Chiu SH.

Drug Metab Dispos. 1996 Jul;24(7):753-60.

PMID:
8818572
[PubMed - indexed for MEDLINE]
20.

Drug-protein conjugates--IV. The effect of acute renal failure on the disposition of [14C]captopril in the rat.

Yeung JH, Breckenridge AM, Park BK.

Biochem Pharmacol. 1983 Sep 1;32(17):2467-72.

PMID:
6351864
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk